Covering all aspects of the pharma industry and across all therapeutic areas, Kevin has interviewed pretty much all the leading figures in the sector. A regular attendee at financial and medical conferences (and moderating at some), he has also appeared on BBC television and radio, ITV and Channel 4 to discuss the industry. Fluent in Spanish, he previously worked as a journalist on rock/pop music publications, was chief sub editor at Catholic newspaper The Universe and contributed articles to the likes of The Independent and the Manchester Evening News on football.
Latest from Kevin Grogan
Panellists at BIO-Europe Spring in Lisbon have welcomed the resurgence of interest in brain-related disorders
The Germany-based family-owned company, which has posted a decent set of financials for 2025 driven by Jardiance and Ofev, is particularly concerned about the red tape involved in getting clinical trials off the ground.
The German biotech hopes to start Phase IIb trials soon of the oral complement C5a inhibitor in the extremely competitive hidradenitis suppurativa market.
Phase II results evaluating the anti-TSLP drug bosakitug are expected in the fourth quarter. Aclaris is pitching the asset as having best-in-class potential in a currently open field.
The mineralocorticoid receptor antagonist, which will be a key driver at the German group in the post-Xarelto world, significantly delayed kidney disease progression in non-diabetic patients in another successful late-stage trial.